EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

HDAC inhibitors: a potential new category of anti-tumor agents



HDAC inhibitors: a potential new category of anti-tumor agents



Cellular & Molecular Immunology 4(5): 337-343



Over the past years, it has been found that the epigenetic silence of tumor suppressor genes induced by overexpression of histone deacetylases (HDACs) plays an important role in carcinogenesis. Thus, HDAC inhibitors have emerged as the accessory therapeutic agents for multiple human cancers, since they can block the activity of specific HDACs, restore the expression of some tumor suppressor genes and induce cell differentiation, growth arrest and apoptosis. To date, the precise mechanisms by which HDAC inhibitors induce cell death have not yet been fully elucidated and the roles of individual HDAC inhibitors have not been identified. Moreover, the practical uses of HDAC inhibitors in cancer therapy, as well as their synergistic effects with other therapeutic strategies are yet to be evaluated. In this review article, we discuss briefly the recent advances in studies of the developments of anti-cancer HDAC inhibitors and their potential clinical value.

(PDF emailed within 1 workday: $29.90)

Accession: 053460503

Download citation: RISBibTeXText

PMID: 17976313



Related references

Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents. Bioorganic & Medicinal Chemistry Letters 24(19): 4768-4772, 2015

Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents. Bioorganic & Medicinal Chemistry Letters 23(17): 4790-4793, 2014

VEGF receptor tyrosine kinase inhibitors as potential anti-tumor agents. Proceedings of the American Association for Cancer Research Annual Meeting (41): 566-567, March, 2000

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. British Journal of Haematology 162(4): 559-562, 2013

HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Pancreatology 12(2): 146-155, 2012

Design and synthesis of small molecule inhibitors of the MDM2-p53 interaction as potential anti-tumor agents. Proceedings of the American Association for Cancer Research Annual Meeting 40: 622, March, 1999

Potential anti tumor agents part 6 possible irreversible inhibitors of ribo nucleoside di phosphate reductase. Journal of Medicinal Chemistry 15(11): 1154-1158, 1972

Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2. European Journal of Medicinal Chemistry 95: 104-115, 2016

Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity. European Journal of Medicinal Chemistry 89: 628-637, 2015

Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents. European Journal of Medicinal Chemistry 90: 170-183, 2015

Synthesis and biological evaluation of novel oxadiazole derivatives: a new class of thymidine phosphorylase inhibitors as potential anti-tumor agents. Bioorganic & Medicinal Chemistry 22(3): 1008-1015, 2014

Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models. European Journal of Medicinal Chemistry 43(1): 142-154, 2007

HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation. American Journal of Translational Research 6(3): 206-223, 2014

Potential anti tumor agents part 11 inhibitors of alkaline phosphatase an enzyme involved in the resistance of neoplastic cells to 6 thio purines. Journal of Medicinal Chemistry 17(9): 934-938, 1974

TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors. Oncotarget (): -, 2016